# Answers to 3 questions the heart doctor needs to know about neurologically ill patients

2<sup>ND</sup> ANNUAL PVHMC CARDIOVASCULAR SYMPOSIUM 14 MARCH 2020



### Conflicts of interest

- Sometimes neurologists and cardiologists seem like they have conflicts of interest with each other, regarding:
  - Blood pressure: aim low (cardiology) vs aim high (neurology)
  - Anticoagulation: the more the better (cardiology)
     vs less is more (neurology)
  - Doing something (cardiology) vs doing nothing (neurology)



**BLOOD PRESSURE** 

# How high how low?

### ACC/AHA BP guidelines

- Normal< 120/80 mm Hg</li>
- Elevated: SBP 120-129 and DBP< 80 mm Hg;</li>
- Stage 1: SBP 130-139 or DBP 80-89;
- Stage 2: SBP >/=140 or DBP>/=90 mm Hg;
- Hypertensive crisis: SBP>180 and/or DBP>120
- GOAL < 130/80 mm Hg

 But neurologists seem to always want high BP post stroke!!



### ASA ischemic stroke guidelines

3.2. Blood Pressure	COR	LOE
<ol> <li>Hypotension and hypovolemia should be corrected to maintain systemic perfusion levels necessary to support organ function.</li> </ol>	- 1	C-EO

The blood pressure (BP) level that should be maintained in patients with AIS to ensure the best outcome is not known. Some observational studies show an association between worse outcomes and lower BPs, whereas others have not. 116-123 No studies have addressed the treatment of low BP in patients with stroke. In a systematic analysis of 12 studies comparing the use of IV colloids and crystalloids, the odds of death or dependence were similar. Clinically important benefits or harms could not be excluded. There are no data to guide volume and duration of parenteral fluid delivery. 124 No studies have compared different isotonic fluids.

"Blood pressure level that should be maintained in patients with AIS....is not known"

"...no data..."



### Brain metabolic demand

- Constant energy expenditure
- Brain has poor capacity for anaerobic metabolism, poor O2 storing capacity


TABLE 3

Major organ and tissue masses and whole-body resting energy expenditure (REE)

					<u> </u>
	All subjects	21-30 y (young)	31-50 y (middle-age)	51–73 y	P
Liver (kg)	$1.39 \pm 0.25$	$1.35\pm0.23$	$1.41 \pm 0.25$	$1.41 \pm 0.28$	0.513
Brain (kg)	$1.33 \pm 0.11$	$1.33\pm0.11$	$1.34\pm0.10$	$1.32\pm0.12$	0.766
Heart (kg)	$0.31\pm0.08$	$0.31\pm0.09$	$0.30\pm0.08$	$0.33\pm0.07$	0.327
Kidneys (kg)	$0.29 \pm 0.06$	$0.28 \pm 0.06$	$0.28\pm0.05$	$0.31 \pm 0.06$	0.042




### Permissive hypertension and penumbra



Schematic shows regions beyond an arterial occlusion with border zones among core, penumbra, and benign oligemia. These regions may change over time owing to possible change in leptomeningeal collateral vessels and other toxic metabolic or physiologic processes, including periinfarct depolarization.




### Arterioles and autoregulation





### **PVHMC Stroke order sets**



### Ischemic Stroke Non TPA

If SBP Greater than 220 mmHg and/or DBP Greater than 120 mmHg, begin IV antihypertensive therapy. Maintain goal SI mmHg. Select ONLY one choice from below.

labetalol (Trandate)	10 mg, IV Push, Injection, Once- If SBP greater than 220 mmHg a
labetalol (Trandate)	20 mg, IV Push, Injection, Q20mi If SBP 180-220 mmHg and/or DE
OR (For use in ED or Critical Care ONLY)	
niCARdipine (Cardene) 25 mg/250 mL Sodium Chloride 0.9%	Total Volume (mL): 250, IV Conc: 0.1 mg/mL. Start: 5 mg/hr
OR (For use in ED or Critical Care ONLY)	
clevidipine (Cleviprex) 50 mg/100 mL IV	Total Volume (mL): 100, IV Start: 1 mg/hr. Double the dose (

# Ischemic stroke pre/post TPA

### Pre TPA

ensives		
<u>`</u>	🤌 labetalol (Trandate)	10 mg, IV Push, Injection, Once-Unscheduled for 1 doses, hypertension If SBP GREATER than 185 mmHg or DBP GREATER than 110 mmHg. Give
š.	🥦 labetalol (Trandate)	20 mg, IV Push, Injection, Q20min for 2 doses, PRN hypertension
		If SBP LESS than 185 mmHg and/or DBP LESS than 110 mmHg not reache
<	🦫 OR (For use in ED or Critical Care ONLY)	
69	clevidipine (Cleviprex) 50 mg/100 mL IV	Total Volume (mL): 100, IV
		Conc: 0.5 mg/mL. Start: 1 mg/hr. Double the dose q90sec until SBP within
<	OR use niCARdipine (Cardene) if clevidipine (Cleviprex) is unavailable or contraindicat	ed (For use in ED or Critical Care ONLY).
1	niCARdipine (Cardene) 25 mg/250 mL Sodium Chloride	Total Volume (mL): 250, IV
	0.9%	Conc: 0.1 mg/mL. Start: 5 mg/hr. Titrate: 2.5 mg/hr Q5min until SBP LESS

### Post TPA

9	If SBP Greater than 180 mmHg and/or DBP Greater than 105 mmHg, begin IV antihypertensive therapy. Maintain goal SBP 120-180 mmHg and DBP 70-105
	mmHg. Select ONLY one choice from below.
-	

💆 labetalol (Trandate)	10 mg, IV Push, Injection, Once-Unscheduled for 1 doses, hyperten
	If SBP greater than 180 mmHg and/or DBP greater than 105 mmHg
labetalol (Trandate)	20 mg, IV Push, Injection, Q20min for 2 doses, PRN hypertension
	If SBP 120-180 mmHg and/or DBP 70-105 mmHg not reached after

9	OR (For use in ED or Critical Care ONLY)	
i	niCARdipine (Cardene) 25 mg/250 mL Sodium Chloride	Total Volume (mL): 250, IV

•		-	
0.9%			Conc: 0.1 mg/mL. Start: 1 mg/hr. Titrate: 2.5 mg/hr Q5min until SB

W OK (FOI USE IN ED OF CHICCAL CARE ONLY)	
clevidipine (Cleviprex) 50 mg/100 mL IV	Total Volume (mL): 100, IV

Conc: 0.5 mg/mL. Start: 1 mg/hr. Double the dose q90sec until SBP ...

POMONA VALLEY HOSPITAI

# Ischemic stroke post thrombectomy

<b>(9</b> (	For Re-canalized patients, maintain SBP 100-160 mmHg AND DBP 50-90 mmHg	
Ē	clexidipine (Clexiprex) 50 mg/100 mL IV	Total Volume (mL): 100, IV Conc: 0.5 mg/mL. Start: 1 mg/hr. Double the dose q90sec until SBP
-⟨\$	OR	
Ī	niCARdipine (Cardene) 25 mg/250 mL Sodium Chloride 0.9%	Total Volume (mL): 250, IV Conc: 0.1 mg/mL. Start: 5 mg/hr. Titrate: 2.5 mg/hr Q5min until SB
-⟨₿	OR	
· 🖑	labetalol (Trandate)	10 mg, IV Push, Injection, Once-Unscheduled for 1 doses, hyperten If SBP greater than 160 mmHg AND DBP greater than 90 mmHg. Gi
· 🖑	labetalol (Trandate)	20 mg, IV Push, Injection, Q20min for 2 doses, PRN hypertension If SBP 100-160 mmHg AND DBP 50-90 mmHg not reached after the
<b>%</b>	Fo Non-Re-canalized patients, maintain SBP 100-200 mmHg AND DBP 70-105 mmH	lg 🗘
Ē	clevidipine (Cleviprex) 50 mg/100 mL IV	Total Volume (mL): 100, IV Start: 1 mg/hr. Double the dose q90sec until SBP within 10 mmHg
-⟨%)	OR	
Ē	niCARdipine (Cardene) 25 mg/250 mL Sodium Chloride 0.9%	Total Volume (mL): 250, IV Conc: 0.1 mg/mL. Start: 5 mg/hr. Titrate: 2.5 mg/hr Q5min until SB
-⟨ÿ	OR	
· 🖑	labetalol (Trandate)	10 mg, IV Push, Injection, Once-Unscheduled for 1 doses, hyperten If SBP greater than 200 mmHg AND DBP greater than 105 mmHg. G
· 🖑	labetalol (Trandate)	20 mg, IV Push, Injection, Q20min for 2 doses, PRN hypertension If SBP 100-200 mmHg AND DBP 70-105 mmHg not reached after th



# SAH unsecured protocol

OR iniCARdip 0.9% OR OR iniCARdip 0.9% InicARdip	pine (Cardene) 25 mg/250 mL Sodium Chloride	Total Volume (mL): 100, IV Conc: 0.5 mg/mL. Start: 1 mg/hr. Double the dose q90sec until S
niCARdip 0.9%  OR  labetalol  labetalol  To mainta clevidipin		
niCARdip 0.9%  OR  labetalol  labetalol  To mainta clevidipin	pine (Cardene) 25 mg/250 ml. Sodium Chloride	
O.9% OR labetalol labetalol To mainta	oine (Cardene) 25 mg/250 ml. Sodium Chloride	
labetalol (	yane (estache) 22 mg/230 me sociam emoriae	Total Volume (mL): 250, IV Conc: 0.1 mg/mL. Start: 5 mg/hr. Titrate: 2.5 mg/hr Q5min until
☐ ♣ ☐ labetalol e ♣ ☐ To mainta ☐ ☐ ☐ ☐ clevidipin		
<b>ॐ To mainta</b> ☐ devidipin	(Trandate)	10 mg, IV Push, Injection, Once-Unscheduled for 1 doses, hypert If SBP greater than 140 mmHg AND MAP greater than 100 mmH
□ † clevidipin	(Trandate)	20 mg, IV Push, Injection, Q20min for 2 doses, PRN hypertension If SBP less than 140 mmHg AND MAP less than 100 mmHg not r
	ain SBP LESS than 160 mmHg AND MAP LESS than 110 mmHg	0
/& ∩p	ne (Cleviprex) 50 mg/100 mL IV	Total Volume (mL): 100, IV Start: 1 mg/hr. Double the dose q90sec until SBP within 10 mm
₹ <b>3</b> OK		
0.9%	pine (Cardene) 25 mg/250 mL Sodium Chloride	Total Volume (mL): 250, IV Conc: 0.1 mg/mL. Start: 5 mg/hr. Titrate: 2.5 mg/hr Q5min until
<a>♦ OR</a>		
🗌 🥰 🧬 labetalol (	(Trandate)	10 mg, IV Push, Injection, Once-Unscheduled for 1 doses, hypert If SBP greater than 160 mmHg AND MAP greater than 110 mmH
🗌 🥰 🐧 labetalol (	(Trandate)	20 mg, IV Push, Injection, Q20min for 2 doses, PRN hypertension If SBP less than 160 mmHg AND MAP less than 110 mmHg not r
🤔 To mainta	ain CPP between 60-80 mmHg	0
	ne (Cleviprex) 50 mg/100 mL IV	Total Volume (mL): 100, IV Start: 1 mg/hr. Double the dose q90sec until CPP within 10 mm
< <b>ॐ</b> OR		
□ † niCARdip 0.9%	pine (Cardene) 25 mg/250 mL Sodium Chloride	Total Volume (mL): 250, IV Conc: 0.1 mg/mL. Start: 5 mg/hr. Titrate: 2.5 mg/hr Q5min until
<a>♦ OR</a>		
🗌 🥦 🐧 labetalol (	(Trandate)	10 mg, IV Push, Injection, Once-Unscheduled for 1 doses, hypert
🗌 🧓 🦪 labetalol i		If SBP greater than 140 mmHg. Give each 10 mg over 1 minute

# SAH secured aneurysm and/or clinical vasospasm

	Vasoactive agents	
i	norepinephrine (Levophed) 8 mg/250 mL Sodium Chloride 0.9% IV	Total Volume (mL): 250, IV Goal: SBP 120-220 mmHg. Conc: 32 mCg/mL. Start: 3 mCg/min.
1-21		
		IV
	Sodium Chloride 0.9% IV	Goal: SBP 120-220 mmHg. Conc: 160 mCg/mL. Start: 40 mCg/m
	Antihypertensive therapy	
1	clevidipine (Cleviprex) 50 mg/100 mL IV	Total Volume (mL): 100, IV
		Conc: 0.5 mg/mL. Goal: SBP 120-220 mmHg. Start: 1 mg/hr. Do.
<b>⊘</b>	OR	

Total Volume (mL): 250, IV

Conc: 0.1 mg/mL. Goal: SBP 120-220 mmHg. Conc: 0.1 mg/mL.



niCARdipine (Cardene) 25 mg/250 mL Sodium Chloride

0.9%

### Vasospasm after SAH

- Develops 3-10 days following SAH
- theories: OxyHb stimulates endothelin 1
- > vasoconstrictor
- inhibits the vasodilator nitric oxide


 Tx of SAH: nimodipine, L type Ca channel blocker

### Case: 67 F, H/A x 3 days, SAH, lethargy

- Found to have L ICA aneurysm
- Hosp day 1, embo of L PCOM aneurysm
- VSP
- Induced HTN



### LEFT ICA ANGIOGRAM





### Case, BP trends


12/27/2019 02:00 PST	Systolic Blood Pressure Invasive	154 (H)	(90 - 139)	
12/27/2019 01:45 PST	Systolic Blood Pressure Invasive	147 (H)	(90 - 139)	
12/27/2019 01:30 PST	Systolic Blood Pressure Invasive	137	(90 - 139)	
12/27/2019 01:15 PST	Systolic Blood Pressure Invasive	141 (H)	(90 - 139)	
12/27/2019 01:00 PST	Systolic Blood Pressure Invasive	136	(90 - 139)	




(60 - 89)Diastolic Blood Pressure Invasive 70 Diastolic Blood Pressure Invasive 61 (60 - 89)Diastolic Blood Pressure Invasive 56 (L) (60 - 89)Diastolic Blood Pressure Invasive 58 (L) (60 - 89)Diastolic Blood Pressure Invasive 56 (L) (60 - 89)Mean Arterial Pressure, Invasive 101 (65 - 140)Mean Arterial Pressure, Invasive 92 (65 - 140)Mean Arterial Pressure, Invasive 85 (65 - 140)Mean Arterial Pressure, Invasive 88 (65 - 140)Mean Arterial Pressure, Invasive 85 (65 - 140)

omona Valley Hospital Medical Center

# Chest X ray hospital day 1 and 5







# Neurogenic stunned myocardium and pulmonary edema

- Related to catecholamine surges
- Globalized vs regional hypokinesis
- Takotsubo cardiomyopathy
  - Echocardiography in patient:
  - 12/27/19, EF 60-65%
  - -12/30/19, < 20%
  - 1/7/20, 40-45%, small pericardial effusion
  - 1/21/20, EF 60-65%, small ant, mod post peri. eff.
- Pulmonary edema: rapid changes on CXR



# Case, BP trends

12/27/2019 02:00 PS	T Syste	olic Blood	Pressure	Invasive	154 (H)	(90 -	-Diast	olic	Blood	Pressure	Inva	sive	70	
12/27/2019 01:45 PS	T Syste	olic Blood	Pressure	Invasive	147 (H)	(90 -	-Diast	olic	Blood	Pressure	Inva	sive	61	
12/27/2019 01:30 PS	T_Syste	olic Blood	Pressure	Invasive [	137	(90	-Diast	olic	Blood	Pressure	Inva	sive	56 (	L)
12/27/2019 01:15 PS	T Syste	olic Blood	Pressure	Invasive	141 (H)	(90 -	-Diast	olic	Blood	Pressure	Inva	sive	58 (	L)
12/27/2019 01:00 PS	T Syste	olic Blood	Pressure	Invasive	136	(90 -	-Diast	olic	Blood	Pressure	Inva	sive	56 (	L)
	Mean	Arterial I	Pressure	, Invasiv	e 101	(€	55 - 14	40)						
	Mean	Arterial I	Pressure	, Invasiv	e 92	(6	55 - 14	40)						
	Mean	Arterial I	Pressure	, Invasiv	e 85	(6	55 - 14	40)						
	Mean	Arterial I	Pressure	, Invasiv	e 88	(€	55 - 14	40)						
	Mean	Arterial I	Pressure	Invasiv	e, 85	((6	55 - 14	40)						
1/01/2020 14:45	PST	Systolic	Blood I	Pressure	113	[[	Diast	olic	Bloo	d Press	ure	66		()
)1/01/2020 14:30	PST	Systolic	Blood I	Pressure	107	-	Diast	olic	Bloo	d Press	ure	64		0
)1/01/2020 14:15	PST	Systolic	Blood I	Pressure	99	I	Diast	olic	Bloo	d Press	ure	58	(L)	()
)1/01/2020 14:00	PST	Systolic	Blood I	Pressure	104	[	Diast	olic	Bloo	d Press	ure	55	(L)	()
1/01/2020 13:45	PST	Systolic	Blood	Pressure	115		Diast	olic	Bloo	d Press	ure	67		()
		Mean A	rterial P	ressure,	Cuff	79	(	65 -	140)					
		Mean A	rterial P	ressure,	Cuff	76	(	65 -	140)					
uniona Valley	Hospital Me	Mean A	rterial P	ressure,	Cuff	71	0	65 -	140)			1000		
									_					

Mean Arterial Pressure, Cuff 69


(65 - 140)


### Cardiac output and cerebral perfusion


- 15-20% CO directed to brain
- 750 mL/min at rest
- Cerebral perfusion pressure= mean arterial pressure-intracranial pressure
- CPP = MAP-ICP




# SBP, MAP, CPP trends









# SBP, ICP trends (fx of ICP modulation) day 6




#### POMONA VALLEY HOSPITAL

# CPP, CO, CI trends






### Cardiac Output




#### Cardiac Index



### CPP, CO, CI trends, day 8

©2012 Pomona VallevHospital Medical Center



10:00 PST

14:00 PST

06:00 PST


### Further course

- extubated
- Vasospasm improved
- Echocardiography
  - 12/27/19, EF 60-65%
  - -12/30/19, < 20%
  - 1/7/20, 40-45%, small pericardial effusion
  - 1/21/20, EF 60-65%, small ant, mod post peri. eff.

### HTN and cerebrovascular remodeling

- increase vascular resistance
- Decreased lumen
- Greater wall to lumen ratio
- ?capillary pruning





### SAMMPRIS trial secondary risk factor mgt

- Stenting vs aggressive Medical Management in Prevention of Recurrent Ischemic Stroke
- Goal blood pressure < 140/90 mm Hg (< 130/80 if diabetic)</li>



**BLOOD THINNERS** 

### WHEN AND WHAT TO START



### **Anticoagulants**

- The results of several clinical trials demonstrate an increased risk of bleeding complications with early administration of either UFH or LMWH
- Early administration of UFH or LMWH does not lower the risk of early recurrent stroke, including among persons with cardioembolic sources.
- The role of anticoagulants as an adjunct in addition to mechanical or pharmacological fibrinolysis has not been established.
- The PREVAIL study gives the strongest evidence of the superiority of LMWH in prevention of venous thromboembolism following ischemic stroke.


### Clinical Scenarios

- Hemorrhagic stroke and cardiac history (CAD or AFIB)
  - Unknown source,
  - Known source treated
  - Known source untreated
- Ischemic stroke and cardiac history as above
  - Recanalized
  - Non recanalized
  - Large stroke
  - Small or moderate sized stroke



## 76 year old woman, w/SAH

- 1 month prior, PCI for NSTEMI. Mid LAD DES
- Moderate stenosis of the distal left circumflex artery of 60 to 70% Chronic total occlusion of the right coronary artery
- On aspirin and ticagrelor




### Unclear source of hemorrhage

- Unable to initiate antiplatelets
- Worsening renal failure, unable to do standard protocol repeat catheter angio at SAH day 7-10
- Repeat MRA brain planned, if negative, may consider starting single antiplatelet therapy
- Ultimately may have initiated antiplatelets but she expired (renal failure and complications of that)

# 82 F, SAH, h/o AFIB, on warfarin



POMONA VALLEY HOSPITAL



## Hospital course

- L PICA aneurysm coiling hospital day 1
- d/c on aspirin
- In clinic 1 month post bleed, started on warfarin

## 38 M, AFIB, intracranial R ICA occlusion

- 3<sup>rd</sup> stroke
  - 1 few years ago L MCA
  - 1 in December R MCA
- On warfarin >dabigatran >riveroxaban (current).
   Planned for LAA
   closure but last TEE
   showed thrombus
- Successful recan, no enlargement start aspirin immediately
- d/c on warfarin (hosp day 2)




#### Other scenarios

- Ischemic stroke, no AFIB, no hemorrhagic conversion, small to moderate size: start antiplatelets soon
- Small/mod isch. stroke + AFIB: NOAC or warfarin-bridge w/aspirin, SQ UH or LMWH VTE proph. Dose)
- Ischemic stroke, + AFIB (or no AFIB), large stroke or hemorrhagic conversion, ? Wait 1-2 weeks for anticoag. Start antiplatelet sooner if feasible

## Hypertensive ICH with cardiac hx or AFIB

- 70 F, R BG ICH, AFIB on riveroxiban
- European stroke initiative rec. starting AC 10-14 days post bleed
- CHADSVASC2 vs HASBLED score
- High TE risk, start early 2 wks, high ICH risk start late 4 weeks



#### Intracranial stent

 Tx of symptomatic intracranial atherosclerotic disease causing recurrent stroke despite maximal medical therapy

 Including with aneurysm, may need dual antiplatelet therapy for 6-12 months (single antiplatelet therapy indef.)

Flow diverter for aneurysm,
 similar antiplatelet strategy



Post cardiac cath stroke

# We're right here, why can't we open the vessel

#### Post cath lab

- Causes of stroke
- Small plaque dislodgement causing small stroke
- Ostial injury
- Usually detected in the cath lab recovery area
- TPA time window 3 hours, broad pool of patients,
   4.5 hours up to 80 years/more selective criteria
- Thrombectomy (for large vessel occlusion only, not lacunar stroke) up to 24 hours

## Management

- TPA depends on any anticoagulation received during procedure (if heparin given, need to document normal PTT, similarly with other anticoagulants)
- If anticoagulation given during procedure, may need to rule out intracranial hemorrhage with head CT
- Acute ICH may cause sudden confusion, agitation, increased BP (Cushing reaction)n



## Causes of stroke during cardiac cath

 Internal thoracic artery opposite vertebral artery origin. May injure that

Vertebral artery is post circ. Supplies thalamus


• Thalamic stroke can <u>mimic hemispheric</u> syndrome so can be differentiate post circ from ant circ ©2012 Pomona Valley Hospital Medical Center

## options

- If ICH suspected, need brain parenchymal imaging
- 3D software
- Lci protocol
- Vascular imaging



## LCI Protocol, fluoroscopy equipment



#### Conclusion

- One patient, one physiological system
- Optimize all organ systems for best performance

